524606 BERLDRG

Beryl Drugs Share Price

₹28.28 +1.97 (7.49%)

23 Feb, 2025 15:14

SIP TrendupStart SIP in BERLDRG

Start SIP

Performance

  • Low
  • ₹0
  • High
  • ₹0
  • 52 Week Low
  • ₹0
  • 52 Week High
  • ₹0
  • Open Price₹0
  • Previous Close₹0
  • Volume0

Investment Returns

  • Over 1 Month -21.49%
  • Over 3 Month -13.65%
  • Over 6 Month -8.48%
  • Over 1 Year -35.14%
SIP Lightning

Smart Investing Starts Here Start SIP with Beryl Drugs for Steady Growth!

Invest Now

Beryl Drugs Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

Beryl Drugs Financials

Beryl Drugs Technicals

EMA & SMA

Current Price
₹28.28
+ 1.97 (7.49%)
pointer
  • stock-down_img
  • Bearish Moving Average 14
  • stock-up_img
  • Bullish Moving Average 2
  • 20 Day
  • ₹31.27
  • 50 Day
  • ₹33.49
  • 100 Day
  • ₹34.43
  • 200 Day
  • ₹33.75

Resistance and Support

27.18 Pivot Speed
  • R3 32.40
  • R2 30.34
  • R1 29.24
  • S1 26.08
  • S2 24.02
  • S3 22.92

What's your outlook on Beryl Drugs?

You can only vote for once

Beryl Drugs Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-02-08 Quarterly Results
2024-11-13 Quarterly Results
2024-08-09 Quarterly Results
2024-05-30 Audited Results
2024-04-20 Others

Beryl Drugs F&O

Beryl Drugs Shareholding Pattern

No data available.

About Beryl Drugs

  • NSE Symbol
  • BERLDRG
  • BSE Symbol
  • 524606
  • ISIN
  • INE415H01017

Similar Stocks to Beryl Drugs

Beryl Drugs FAQs

Beryl Drugs share price is ₹28 As on 23 February, 2025 | 15:00

The Market Cap of Beryl Drugs is ₹14.3 Cr As on 23 February, 2025 | 15:00

The P/E ratio of Beryl Drugs is 179.7 As on 23 February, 2025 | 15:00

The PB ratio of Beryl Drugs is 1.6 As on 23 February, 2025 | 15:00

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23